Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprea TherapeuticsAPRE -2.02%30 3-1 Month Momentum % is -13.08% as of Jul. 25, 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,392 Biotechnology companies, Aprea Therapeutics ranks better than 57.61% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-25), Aprea Therapeutics's 3-1 Month Momentum % is -13.08%.
The industry rank for Aprea Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
APRE's 3-1 Month Momentum % is ranked better than 57.61% of 1392
companies
in the Biotechnology industry
Industry Median: -10.615
vs APRE: -13.08
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Aprea Therapeutics 3-1 Month Momentum % Related Terms
APRE vs JSPR, CVKD, BRTX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Aprea Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprea Therapeutics (APRE) has a 3-1 Month Momentum % of -13.08% as of Jul. 25, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Aprea Therapeutics and its competitors. According to the industry distribution chart, Aprea Therapeutics ranks #590 out of 1392 companies in the Biotechnology industry, placing it in the top 42.4%.
Is Aprea Therapeutics' 3-1 Month Momentum % too high?
Aprea Therapeutics' current 3-1 Month Momentum % is -13.08%. Based on the distribution chart, Aprea Therapeutics ranks #590 out of 1392 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' 3-1 Month Momentum % compare to JSPR and CVKD?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #590 out of 1392 companies for 3-1 Month Momentum %. This puts Aprea Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Aprea Therapeutics and its competitors. Aprea Therapeutics's current 3-1 Month Momentum % is -13.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current 3-1 Month Momentum % of -13.08%. The current 3-1 Month Momentum % is -13.08%. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current 3-1 Month Momentum % is -13.08% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score
Get the complete analysis for APRE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRE has been successfully added to your 
